Clinically, molecular methods or drugs can be used to specifically increase the expression of Gcn5 in the periodontal tissue of patients with chronic periodontitis, thereby restoring the osteogenic differentiation ability of PDLSCs and reversing the reduction of alveolar bone mass caused by chronic periodontitis, holding promise to maintain this trait in the periodontal tissues for a long time. Here, KAT2A is linked to periodontitis.